Research progress of myeloproliferative disorders: several clinical problems post the JAK2 mutation era
- Author:
- No author available
- Journal Title:
- JOURNAL OF LEUKEMIA & LYMPHOMA
- Issue:
- 1
- DOI:
- 10.3760/cma.j.issn.1009-9921.2010.01.002
- Key Word:
- 骨髓增殖性疾病;基因,JAK2;突变;诊断;治疗;Myeloproliferation disorders;Gene,JAK2;Mutation;Diagnosis;Therapy
Abstract： This critical review was summarized more systematically about the JAK2V617F mutation of related research progress in myeloproliferative disorders (MPD) research fields and the identification of JAK2V617F mutation represents an important advance in our understanding of MPD was agreed. The authors focused on several sensitive problems of post the JAK2 mutation era, and expressed their opinions. The Guideline of the MPD diagnostic criteria recommended by WHO in 2008 was accepted. The authors recommend the MPD, rather than myeloproliferative neoplasm (MPN). The treatment for the MPD (not including the CML) is recommended. Before the effective targeting of JAK2V617F specific inhibitors for the treatment of the MPD, short-term of use hydroxyurea (HU) was suggested to suppress excessive proliferation of bone marrow of MPD and a long course of treatment application of inteferon-α(IFN-α), and low-dose of aspirin in a timely manner were recommended to prevent thrombosis and other complications.
- [1]尹文杰,刘小鹏,宫立众.真性红细胞增多症转化为急性白血病并发结肠癌一例[J].2009,(8).
- [2]申徐良,陈方平,魏武,等.bcr-abl阴性骨髓增生性疾病患者JAK2V617F点突变检测的临床意义[J].2008,(2).
- [3]刘红星,童春容,蔡鹏,等.多重位点特异性PCR检测骨髓增殖性疾病五种JAK2基因突变[J].2009,(1).
- [4]张苏江,李伟达,宋君红,等.等位基因特异性聚合酶链反应结合测序对骨髓增殖性疾病JAK2 V617F点突变的研究[J].2007,(30).
- [5]Bench AJ,Boyd EM,Scott MA,etc.Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.[J].2005,365(9464).
- [6]张之南, 沈悌主编.血液病诊断及疗效标准[M].2007.
- [7]Skoda RC,Passweg JR,Passamonti F,etc.A gain-of-function mutation of JAK2 in myeloproliferative disorders.[J].2005,352(17).
- [8]Vigna E,Lucia E,Qualtieri G,etc.The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods.[J].2008,49(10).
- [9]Lodish HF,Beer PA,Levine RL,etc.JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.[J].2007,356(5).
- [10]Huntly BJ,Frohling S,D'Andrea A,etc.Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.[J].2005,7(4).
- [11]Gotlib J,Jamieson CHM,Lay M,etc.The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation[J].2006,103(16).
- [12]Chloé, James,Valérie, Ugo,Jean-Pierre, Le Couédic,etc.A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.[J].2005,434(7037).
- [13]Ruben A, Mesa.Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders.[J].2007.
- [14]Tefferi A,Vardiman JW.Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.[J].2008,22(1).
- [15]Garber K.JAK2 inhibitors: not the next imatinib but researchers see other possibilities.[J].2009,101(14).
- [16]Flowers ME,Linenberger M,Gooley TA,etc.Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.[J].2007,13(3).
- [17]Josef T, Prchal.Philadelphia chromosome-negative myeloproliferative disorders: an historical perspective.[J].2008.